Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain

被引:15
作者
Alonso, R [1 ]
Gnanadicom, H [1 ]
Fréchin, N [1 ]
Fournier, M [1 ]
Le Fur, G [1 ]
Soubrié, P [1 ]
机构
[1] Sanofi Rech, Dept Neuropsychiat, F-34184 Montpellier 04, France
关键词
c-fos; dopamine receptors; enkephalin; zif268;
D O I
10.1046/j.1460-9568.1999.00506.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A remarkable feature of dopamine functioning is that the concomitant activation of D1-like and D2-like receptors acts to intensify the expression of various dopamine-dependent effects, in particular the expression of the immediate-early genes, c-fos and zif268. Using non-peptide neurotensin receptor antagonists, including SR48692, we have determined that blockade of neurotensin receptors reduced the cooperative responses of direct acting D2-like (quinpirole) and partial D1-like (SKF38393) dopamine agonists on the expression of Fos-like antigens and zif268 mRNA. Pretreatment with SR48692 (3 and 10 mg/kg) reduced the number of Fos-like immunoreactive cells produced by the combined administration of SKF38393 (20 mg/kg) and quinpirole (1 mg/kg) in the caudate-putamen, nucleus accumbens, globus pallidus and ventral pallidum. High-affinity neurotensin receptors are likely to be involved in these D1-like/D2-like cooperative responses, as compounds structurally related to SR48692, SR48527 (3 mg/kg) and its (-)antipode, SR49711 (3 mg/kg), exerted a stereospecific antagonism in all selected brain regions. Pretreatment with SR48692 (10 mg/kg) also diminished Fos induction by the indirect dopamine agonist, cocaine (25 mg/kg), particularly at the rostral level of the caudate-putamen. In situ hybridization experiments in the caudate-putamen indicated that SR48692 (10 mg/kg) markedly reduced zif268 mRNA labelling produced by SKF38393 plus quinpirole in cells not expressing enkephalin mRNA, but was unable to affect the concomitant decrease of zif268 mRNA labelling in enkephalin-positive cells. Taken together, the results of the present study indicate that neurotensin is a key element for the occurrence of cooperative responses of D2-like and partial D1-like agonists on immediate-early gene expression.
引用
收藏
页码:967 / 974
页数:8
相关论文
共 34 条
[1]  
AUDINAT E, 1989, EXP BRAIN RES, V78, P358
[2]   EFFECTS OF DOPAMINE AUTORECEPTOR STIMULATION ON THE RELEASE OF COLOCALIZED TRANSMITTERS - INVIVO RELEASE OF DOPAMINE AND NEUROTENSIN FROM RAT PREFRONTAL CORTEX [J].
BEAN, AJ ;
DURING, MJ ;
ROTH, RH .
NEUROSCIENCE LETTERS, 1990, 108 (1-2) :143-148
[3]   STRIATAL NEURONS EXPRESS INCREASED LEVEL OF DOPAMINE D2 RECEPTOR MESSENGER-RNA IN RESPONSE TO HALOPERIDOL TREATMENT - A QUANTITATIVE INSITU HYBRIDIZATION STUDY [J].
BERNARD, V ;
LEMOINE, C ;
BLOCH, B .
NEUROSCIENCE, 1991, 45 (01) :117-126
[4]   REVIEW - D1 DOPAMINE RECEPTOR - THE SEARCH FOR A FUNCTION - A CRITICAL-EVALUATION OF THE D1/D2 DOPAMINE RECEPTOR CLASSIFICATION AND ITS FUNCTIONAL IMPLICATIONS [J].
CLARK, D ;
WHITE, FJ .
SYNAPSE, 1987, 1 (04) :347-388
[5]   CHOLECYSTOKININ-DOPAMINE INTERACTIONS [J].
CRAWLEY, JN .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (06) :232-236
[6]  
Gerfen CR, 1995, J NEUROSCI, V15, P8167
[7]   AMPHETAMINE AND COCAINE INDUCE DRUG-SPECIFIC ACTIVATION OF THE C-FOS GENE IN STRIOSOME MATRIX COMPARTMENTS AND LIMBIC SUBDIVISIONS OF THE STRIATUM [J].
GRAYBIEL, AM ;
MORATALLA, R ;
ROBERTSON, HA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6912-6916
[8]  
Gully D, 1997, J PHARMACOL EXP THER, V280, P802
[9]   BIOCHEMICAL AND PHARMACOLOGICAL PROFILE OF A POTENT AND SELECTIVE NONPEPTIDE ANTAGONIST OF THE NEUROTENSIN RECEPTOR [J].
GULLY, D ;
CANTON, M ;
BOIGEGRAIN, R ;
JEANJEAN, F ;
MOLIMARD, JC ;
PONCELET, M ;
GUEUDET, C ;
HEAULME, M ;
LEYRIS, R ;
BROUARD, A ;
PELAPRAT, D ;
LABBEJULLIE, C ;
MAZELLA, J ;
SOUBRIE, P ;
MAFFRAND, JP ;
ROSTENE, W ;
KITABGI, P ;
LEFUR, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) :65-69
[10]   Neuropharmacological profile of non-peptide neurotensin antagonists [J].
Gully, D ;
Jeanjean, F ;
Poncelet, M ;
Steinberg, R ;
Soubrie, P ;
LeFur, G ;
Maffrand, JP .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1995, 9 (06) :513-521